Clinical-stage biopharmaceuticals (TNF-α inhibitors and CBD therapeutics)
Strategic Profile
MYMD-1 is distinguished as a first-in-class oral treatment shown to reduce TNF-α and inflammation without infusion or injection, with an advantage over currently available TNF-α blockers, none of which are dosed orally. The company's second platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy as a novel synthetic derivative of cannabidiol addressing the growing CBD market.
Cyborg Score Rationale
Early-stage pipeline with two promising platforms showing Phase 2 data (MYMD-1) and positioned in high-unmet-need markets (TNF-inhibitors, CBD therapeutics). However, the company has only nine employees, with six primarily involved in R&D, creating execution risk. Recent rebranding (July 2024) suggests strategic repositioning but may indicate market/investor pressures.
Top Insights
Company has completed Phase 2 studies of MYMD-1 for sarcopenia/frailty and early-stage trials for rheumatoid arthritis with potential to expand into other applications
In May 2024, secured $7 million in strategic investments led by PharmaCyte Biotech (Nasdaq: PMCB) in private placement funding rounds
Owns full rights to intellectual property with 15 active US patents and 28 pending patents internationally
Rebranded to TNF Pharmaceuticals, Inc. effective July 24, 2024, reflecting strategic focus on TNF-alpha inhibitor platform
Named Competitors
Enbrel/Etanercept — TNF-α inhibitor injection therapy for autoimmune diseases
Remicade/Infliximab — TNF-α inhibitor infusion therapy for autoimmune diseases
Epidiolex — FDA-approved CBD-derived therapy for seizures
Recent Developments
(July 2024) Rebranded to TNF Pharmaceuticals, Inc. and began trading under new ticker symbol TNFA
(May 2024) Secured $7 million in strategic investments from PharmaCyte Biotech and existing shareholders
(June 2026) Regained compliance with Nasdaq minimum bid price requirement for continued listing
Open the full interactive MyMD Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.